rinatabart sesutecan (rina-s, pro1184, gen1184) for advanced solid tumors (gct1184-01/ pro1184-001)

Conditions: High Grade Epithelial Ovarian Cancer; High Grade Serous Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Endometrial Cancer; Non-small Cell Lung Cancer; Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC); Mesothelioma; Breast Adenocarcinoma; Triple Negative Breast Cancer; Hormone Receptor-positive/Her2 Negative Breast Cancer; Platinum-resistant Ovarian Cancer (PROC); Platinum Sensitive Ovarian Cancer (PSOC); Primary Refractory Ovarian Cancer; Uterine Cancer

Summary: this study will test the safety, including side effects, and determine the characteristics of a drug called rina-s in participants with solid tumors. participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

this is a phase 1/2 study of rina-s; also known as gen1184, formerly known as pro1184, a folate receptor alpha (frα) targeted antibody-drug conjugate, to evaluate the safety, tolerability, pharmacokinetics (pk), and antitumor activity of rina-s in participants with selected locally advanced and/or metastatic solid tumors, including epithelial ovarian cancer, endometrial cancer, breast cancer, non-small cell lung cancer, and mesothelioma. the study consists of multiple parts: part a: monotherapy cohorts part b: tumor-specific monotherapy dose-expansion cohorts part c: platinum-resistant ovarian cancer (proc) cohort part d: combination therapy cohorts part f: a monotherapy endometrial cancer cohort participants will continue to receive study treatment until the first instance of disease progression, unacceptable toxicity, investigator decision, consent withdrawal, study termination by the sponsor, pregnancy, or death.

Eligibility criteria:
inclusion criteria: part a and b: * histologically or cytologically confirmed metastatic or unresectable solid malignancy including ovarian cancer (must have epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer), endometrial cancer, non-small cell lung cancer (part a), egfr-mutated nsclc (part b), breast cancer (hormone receptor positive, her2-negative and triple-negative) (part a), mesothelioma. * previously received therapies known to confer clinical benefit. * measurable disease per recist v1.1 for all tumor types other than pleural mesothelioma which will use mrecist v1.1 at baseline. part c: participants must have histologically or cytologically confirmed metastatic or unresectable epithelial ovarian cancer as specified below. * high grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (excluding endometrioid, clear cell carcinomas, mucinous, low grade, and those with a sarcomatous or neuroendocrine element) * participants must have received 1 to 3 prior lines of therapy. participants who had 1 to 4 prior lines of therapy are allowed if mirvetuximab soravtansine (mirv) was the last line of therapy. participants must have progressed radiographically on or after their most recent line of therapy. * participants must have platinum-resistant ovarian cancer. * participants must have received prior bevacizumab. * participants with known or suspected deleterious germline or somatic brca mutations (as determined by food and drug administration \[fda\]-approved test in a clinical laboratory improvement amendments \[clia\]-certified laboratory) and who achieved a complete or partial response to platinum-based chemotherapy must have been treated with a poly adp-ribose polymerase (parp) inhibitor as maintenance treatment. * participants must have known frα status based on an fda approved test. those who are frα positive must have previously received mirv, unless the participant has a documented medical exception. * participants who are frα negative, in accordance with the fda approved test (ventana folate receptor \[folr1\] rxdx assay), and were treated with mirv, are excluded. * measurable disease per the recist v1.1 at baseline. part d: cohort d1 (rina-s+carboplatin): * participants must have platinum-sensitive ovarian cancer. * participants must have received 1 to 3 prior lines of therapy. cohort d2 (rina-s+bevacizumab): * participants must have primary platinum-refractory, platinum-resistant, or platinum-sensitive ovarian cancer. * participants with primary platinum-refractory ovarian cancer must have received ≤2 prior lines of therapy. primary platinum-refractory ovarian cancer is defined as a lack of response or by progression within 91 days after completing front-line platinum containing therapy. * participants must have received 1 to 3 prior lines of therapy for platinum-resistant ovarian cancer (proc), and up to 4 prior lines of therapy for platinum-sensitive ovarian cancer (psoc). prior treatments may have included bevacizumab, parp inhibitor, and mirv. * participants with psoc must have disease progression on or after maintenance treatment, or at least 6 months (\>183 days) or more from the last dose of platinum-based therapy. cohort d3 (rina-s+pembrolizumab): * endometrial cancer (any subtype excluding sarcoma). * participants must have received prior platinum-based chemotherapy for recurrent or advanced disease. part f: * participants must have histologically or cytologically confirmed endometrial cancer as specified below. * advanced, recurrent, metastatic, or primary unresectable endometrial cancer (any subtype excluding neuroendocrine tumors, carcinosarcoma, or endometrial sarcoma) * participants must have received 1 to 3 prior lines of therapy in advanced, recurrent, or metastatic setting, and must have progressed radiographically on or after their most recent line of therapy: * participants must have received prior platinum-based chemotherapy and a programmed death-ligand 1 (pd-\[l\])1 inhibitor. * participants who progress \>12 months after completion of prior adjuvant or neoadjuvant platinum-based chemotherapy must receive 1 additional cytotoxic systemic treatment prior to enrollment in this study. * hormonal therapy alone (i.e., without chemotherapy) will not be counted as a separate line of therapy. * measurable disease per the recist version 1.1 at baseline. exclusion criteria: * history of (non-infectious) interstitial lung disease (ild)/pneumonitis that required steroids within the past 2 years, has current ild/pneumonitis, or where suspected ild/pneumonitis cannot be ruled out by imaging at screening. * use of a strong cytochrome p450 3a (cyp3a) inhibitor within 14 days (dose escalation only). * prior therapy with a topoisomerase 1 inhibitor-based antibody drug conjugate. note: other protocol-defined inclusion/exclusion may apply.

Keywords: antibody-drug conjugate folate receptor alpha folate receptor solid tumor ovarian cancer primary peritoneal carcinoma fallopian tube cancer endometrial cancer non-small cell lung cancer mesothelioma breast cancer triple negative breast cancer hormone receptor-positive (hr+)/human epidermal growth factor receptor 2 negative (her2-) breast cancer topoisomerase i inhibitor proc epidermal growth factor receptor (egfr)-mutated nsclc